Nvelop Launches with Dual Platforms for In Vivo Delivery of NextGen Genetic Medicines

Rare Daily Staff

Nvelop Therapeutics formally announced its launch with $100 million in funding to develop programmable, non-viral vehicles for in vivo cell-specific delivery of a broad set of gene edited therapeutic cargoes.

Nvelop Therapeutics was founded in 2022 to address the challenge of efficiently delivering therapeutic cargoes to target cells in vivo and is backed by investors that include Newpath Partners, Atlas Venture, F-Prime Capital, 5AM Ventures, GV, and ARCH Venture Partners.

The company’s modular platforms are based on two in vivo validated delivery approaches independently developed at the Broad Institute of MIT and Harvard, and Massachusetts General Hospital by leaders in the gene editing field – co-founders David Liu, and Keith Joung. These novel approaches are designed to realize the potential of genetic medicines by addressing the limitations of currently available delivery platforms.

Nvelop says its approach can improve delivery efficiency, enabling potent therapies to target diseases across multiple tissues in which a high degree of activity is required for clinical benefit, and tissue specificity, driving targeted in vivo delivery to cells and tissues that have been historically difficult to reach. This will allow delivery of a wide range of cargo types and sizes, including transiently expressed proteins (e.g., base and prime editor ribonucleoproteins – or RNPs), and also confer safety advantages, expanding the number of diseases treatable with genetic medicines. Increased safety is achieved by optimized RNP cargoes and intricately engineered particles with the potential to be fully humanized.

One of Nvelop’s platform technologies, with in vivo data, has been published in peer-reviewed journals, including Cell (2022) and Nature Biotechnology (2024). In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

“The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s CEO. “With the combination of best-in-class technologies, scientific co-founders with a deep track record in cell and gene therapy, and a team that has pioneered the development of some of the first approved therapies in the field, Nvelop is uniquely positioned to unlock the promise of genetic medicines.”

Photo: Jeff Walsh, CEO of Nvelop